health-and-biotech21.59 min read
NIH Launches Public-Private Cancer Vaccine Initiative to Accelerate Personalized Treatments
3 days ago•Source: Yahoo Finance
Health And Biotech News
The latest health and biotech stories, each synthesized from multiple sources with added background and context.
Featured Health And Biotech Stories
View original source
2.06 min•15 days ago
Merck and Daiichi Withdraw Lung Cancer Drug Filing After FDA Rejection
Merck and Daiichi Sankyo voluntarily withdrew their accelerated approval application for the antibody-drug conjugate ifinatamab deruxtecan (I-DXd) in small cell lung cancer after the FDA deemed the data insufficient. This setback delays revenue from a $4 billion partnership and impacts competitors like Amgen and GSK.
More Top Stories
2
3
Viking Therapeutics shares jump 38% as VK2735 data shows weight loss maintenance on reduced dosing
Yahoo Finance•21 days ago
More Health And Biotech Stories
Cancer Vaccine Market Set to Hit 36% CAGR as mRNA Breakthroughs Expand Beyond Melanoma
The global cancer vaccine market, valued at $335 million in 2025, is projected to grow at a 36% compound annual rate through 2036. This expansion is driven by the recent Phase 3 success of Moderna and Merck’s personalized mRNA vaccine for melanoma, alongside a broadening pipeline targeting lung, prostate, and pancreatic cancers. While the US dominates current sales, analysts note a persistent gap between early immune responses and late-stage clinical efficacy.
Novartis Lp(a) Failure Casts Shadow on Cardiovascular Drug Race
Novartis reported that its experimental heart drug pelacarsen failed to prevent heart attacks or strokes in a major trial, despite significantly lowering the targeted blood protein Lp(a). This setback, following recent failures by Novo Nordisk, has spooked investors and raised doubts about the viability of the entire Lp(a) drug class, though analysts note the hypothesis is not yet disproven.
"Evaxion's Breakthrough: AI-Driven Cancer Vaccine Boosts Stock by 30%"
Evaxion Biotech is leveraging AI-Immunology™ to develop tailored cancer vaccines targeting Endogenous Retroviruses (ERVs), an untapped source of tumor antigens, with the goal of providing treatment solutions to cancer patients unresponsive to conventional immunotherapy. The company aims to generate Proof-of-Concept data by the second half of 2024 and has presented recent insights at the American Society of Hematology Annual Meeting. ERVs, remnants of ancient viruses overexpressed in cancer, are promising targets for cancer vaccines, and AI-Immunology™ plays a crucial role in identifying therapeutically relevant ERV tumor antigens from genomic patient tumor data. Evaxion's AI-Immunology™ platform offers a scalable and adaptable approach to vaccine discovery for infectious diseases and cancers, revolutionizing the landscape of immunotherapy with personalized medicine.